Clinical bottom line
Serum fibroblast activation protein (FAP) shows promise as a non-invasive biomarker for monitoring liver fibrosis progression and therapeutic response. Early clinical studies using PET imaging and serological assays indicate that FAP expression correlates with fibrotic activity in the liver, potentially enabling more precise staging and dynamic assessment of fibrosis. However, current evidence remains preliminary and largely hypothesis-generating. Larger, prospective studies are needed to validate serum FAP quantification against established fibrosis markers and histology before routine clinical adoption.
What the evidence shows
Fibroblast activation protein (FAP) is a cell surface serine protease predominantly expressed by activated fibroblasts in fibrotic tissue and the tumor microenvironment. Its enzymatic activity contributes to extracellular matrix remodeling, making it a biologically plausible marker of fibrogenesis.
Recent imaging studies have leveraged radiolabeled FAP inhibitors for PET scanning to visualize fibrotic activity in vivo. Li et al. (2024) demonstrated that [^18F]AlF-ND-bisFAPI PET imaging could non-invasively monitor liver fibrosis progression in patients, with tracer uptake correlating with fibrosis severity assessed by biopsy and elastography. This approach offers a dynamic, spatially resolved assessment of fibrotic burden beyond static serum markers.
Complementing imaging, serological quantification of FAP activity has been explored. Pedersen et al. (2024) reported that serum levels of FAP-cleaved type III collagen fragments reflect FAP enzymatic activity and correlate with fibrotic remodeling. This biomarker showed potential for monitoring fibrosis progression and response to antifibrotic therapies in cancer and lung fibrosis models, suggesting translational relevance to liver disease.
Earlier foundational work by Brennen et al. (2007) established FAP as a diagnostic marker and therapeutic target in fibrotic tumors, underscoring its role in pathological fibroblast activation. Mathematical modeling studies (Nouran et al., 2026) further support the concept that targeting FAP activity could modulate fibrotic tissue dynamics, reinforcing the biomarker’s relevance.
Together, these data suggest that serum FAP measurement, possibly combined with FAP-targeted imaging, could provide a novel, non-invasive window into liver fibrosis activity, complementing existing tools like elastography and serum fibrosis panels.
Caveats and uncertainty
Despite promising early data, several limitations temper enthusiasm for immediate clinical implementation. Most studies to date are small, single-center, or preclinical, with limited longitudinal follow-up. The specificity of serum FAP for liver fibrosis versus other fibrotic or inflammatory conditions remains incompletely characterized.
The kinetics and standardization of serum FAP assays require further optimization. Variability in assay platforms and lack of established reference ranges hinder cross-study comparisons. Moreover, the incremental value of FAP measurement over established fibrosis biomarkers such as M2BPGi or keratin-18 fragments is not yet defined.
PET imaging with FAP inhibitors, while innovative, is resource-intensive and not widely available. Its clinical utility must be balanced against cost, radiation exposure, and accessibility compared to simpler serum tests.
Finally, the direct impact of FAP biomarker-guided management on patient outcomes has not been demonstrated. Whether FAP measurement can reliably predict fibrosis regression or guide therapy adjustments remains hypothetical.
How this may change practice
If validated, serum FAP quantification could become a useful adjunct in the hepatology clinic for dynamic fibrosis assessment. It may help identify patients with active fibrogenesis who could benefit from early intervention or closer monitoring. Combined with FAP-targeted PET imaging, it could refine fibrosis staging and detect heterogeneous fibrotic activity within the liver.
This biomarker could also facilitate clinical trials by providing a sensitive pharmacodynamic readout of antifibrotic therapies, accelerating drug development. However, routine clinical use awaits robust validation in diverse liver disease populations, assay standardization, and demonstration of cost-effectiveness.
Clinicians should remain aware of emerging data but continue to rely on established fibrosis assessment tools until further evidence accrues. Integration of FAP biomarkers into practice will require multidisciplinary collaboration among hepatologists, radiologists, and laboratory scientists.